Data from a Phase III trial of Vertex Pharmaceuticals’ Kalydeco (ivacaftor) has been published ion the New England Journal of Medicine.

Kalydeco targets the defective protein responsible for cystic fibrosis.

The STRIVE study evaluated 161 patients aged 12 or older who received at least one dose of either Kalydeco as a single 150mg tablet or placebo twice daily and showed improvements in lung function and other measures of disease throughout the 48-week study.

The study reported a 10.6% mean absolute improvement and 16.7% relative mean improvement in lung function from baseline compared to placebo through to week 24.

Through to week 48, the mean absolute improvement in lung function was 10.5% and the relative mean improvement was 16.9% from baseline compared to placebo.

The company has submitted a new drug application to the US Food and Drug Administration and a marketing authorisation application to the European Medicines Agency.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.